Silence has been a pioneer in the RNAi field for over 18 years. Through the efforts of our skilled researchers and scientists, we have established an innovative platform with broad intellectual property protection. Using our RNAi-directed platform technologies, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. We are currently focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron overload disorders, and complement-mediated disorders.
Annual Report 2019Download
Half Year Results 2020391KB Download
Full Year Results 2019361KB Download
Half Year Results 2019345KB Download
Full Year Results 2018371KB Download
Half Year Results 2018367KB Download
Annual Report 20191MB Download
Annual Report 20183MB Download
Annual Report 20172MB Download
Annual Report 20161MB Download
Annual Report 2015978KB Download
Silence Therapeutics FY19 Results Announcement175KB Download
Collaboration with AstraZeneca and R&D Update176KB Download
Silence Therapeutics HY20 Results Announcement955KB Download
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.